Divis Laboratories - Carotenoids

			Generic API's

			Intermediates

			Peptide Building Blocks

			Carotenoids (Synthetic) and Nutraceuticals

			Future Generics

News & Events


	Divi’s Labs PAT for Q2 grows by 49% to Rs.135 crores

	Divi’s Labs PAT for Q1 grows by 45% to Rs.94 crores

	Divi’s Labs PAT for FY08 grows by 87% to Rs.348 crores

	Divi’s Labs PAT for Q3 grows by 216% to Rs.99 crores

	Divi’s Labs PAT for Q2 grows by 204% to Rs.91 crores

	Divi’s Labs PAT for Q1 grows by 153% to Rs.65 crores

	Divi’s Labs PAT for FY07 grows by 167% to Rs.186 crores

	Divi’s Labs Q3 total income grows by 38% to Rs.152 crores

	Divis successful US-FDA inspection for Unit II

	Divi’s Labs Q2 total income grows by 97% to Rs.165 crores.

	Divi's Labs Q1 total income grows by 142% at Rs.165 crores

	Divi's Laboratories earns a net of 70 crores on an income of Rs.392 crores in FY06

	Divi's gets nod for pharma SEZ

	Divis Laboratories earns a PBT of Rs.43 Crores in First-Half of FY06

	Divis Laboratories earns a total income of Rs.68 Crores in Q1 of FY06

	Divis Laboratories earns a total income of Rs.365 Crores in FY05

	Divis Laboratories earns a Net of Rs.105 Crores in Q3

	Divis Laboratories earns a PBT of Rs.45 Crores in First-Half of FY05

	Divis Laboratories earns a Net of Rs.14 Crores in Q1

Divis has succeeded in developing multistep total synthesis of important carotenoids like Betacarotene, Lycopene, Astaxanthin, Canthaxanthin etc.

ASTAXANTHIN CAS No [472-61-7]

BETA - CAROTENE CAS No [7235-40-7]

CANTHAXANTHIN CAS No [514-78-3]

Genistein

Website Designed by Sumudra